Fald i knoglemineraltætheden i rygsøjlen samt ændringer i knoglebiomarkørerne fra baseline var signifikant større i tenofovirdisoproxilfumarat- behandlingsgruppen ved 144 uger.
Decreases in bone mineral density of spine and changes in bone biomarkers from baseline were significantly greater in the tenofovir disoproxil fumarate treatment group at 144 weeks.